The antioxidant tempol prevents the onset of pre-eclampsia in pregnant mice, a finding that further implicates oxidative stress in the illness, which is widespread among pregnant women.
According to lead researcher Darren S. Hoffmann, tempol
- cut fetal deaths in half
- normalized birth weight and placental development
- prevented the onset of high blood pressure and proteinuria
"The results strongly suggest that antioxidant therapy will be useful for women with pre-eclampsia," Hoffmann said. Hoffmann received a Caroline tum Suden/ Frances A. Hellebrandt Professional Opportunity Award from The American Physiological Society (APS) for the exemplary research. The paper will be presented in an APS session at Experimental Biology 2006.
Pre-eclampsia has been recognized as a threat to maternal health for centuries and is the leading cause worldwide of mortality during pregnancy. But its cause has remained a mystery, Hoffmann said. The condition is marked by high blood pressure and kidney dysfunction, and occurs in about 5% of pregnancies. The only way to reverse the condition, which occurs in the third trimester, is to induce early delivery, he said.
The condition is often treated by complete bed rest. But managing the condition is a delicate balance pitting the needs of the mother, who is suffering a potentially harmful condition, against the needs of the fetus, which is best served by remaining in the womb.
Pre-eclampsia occurs when the placenta fails to develop properly and the fetus is unable to get adequate nutrients from the mother, Hoffmann explained. That sets off a cascade of events that can result in damage not only to the fetus, but also to the mother's kidney and blood vessels. If left unchecked, the condition could lead to eclampsia, an even more serious illness marked by seizures.
In areas where women do not have access to medical care, the condition causes death in one in 650 pregnant women, Hoffmann said. Even in the U.S., pre-eclampsia is the leading cause of maternal mortality. And even when the condition is well managed, it often results in having to induce a premature birth, which carries substantial economic cost. On average, neonatal care for premature infants costs $40,000, he said.
Oxidative stress is a disturbance in the oxidant-antioxidant balance and is caused by reactive oxygen species (ROS) -- negatively charged oxygen-containing molecules -- that includes superoxide, Hoffmann said. ROS can damage the cell's DNA, proteins, lipids and can affect the cell's signaling mechanisms. High levels of ROS are implicated in cardiovascular disease, cancer, and other diseases.
Cells produce an antioxidant, superoxide dismutase, to deal with the reactive oxygen species. Superoxide dismutase grabs the superoxide molecule and, over several steps, neutralizes it by converting it to water and oxygen.
Pre-eclampsia is not well understood because it is difficult to conduct experiments in high-risk pregnant women, and there haven't been good animal models for the condition, Hoffmann said. But the Iowa lab has begun using a mouse strain which has moderately elevated blood pressure, because women who have moderately elevated blood pressure have a five times greater chance of developing pre-eclampsia compared to women with normal blood pressure.
"We discovered these mice develop pregnancy-induced high blood pressure, proteinuria and placental abnormalities," Hoffmann said. The mice, like humans, are more likely to have impaired placental development and their fetuses are smaller, further making them a good model for the research.